Tolerability and Pharmacokinetics/-Dynamics of Single Rising Doses BIBT 986 BS in Healthy Male Subjects
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to assess the tolerability of BIBT 986 BS after intravenous infusions of 0.1, 0.3, 1.0,
2.5, 5.0, and 10 mg, to assess the pharmacokinetics of BIBT 986 BS after intravenous infusion
and to assess the effect of BIBT 986 BS on blood coagulation parameters